Bristol/Pfizer Offer Some Good Apixaban Results, With Key Study Against Warfarin On Track To Report 2H 2011
This article was originally published in The Pink Sheet Daily
Executive Summary
The experimental anticoagulant's win over aspirin in patients intolerant to or unsuitable for warfarin therapy may allow a narrower indication.
You may also be interested in...
Doubts Linger Over Whether AVERROES Gives Any Advantage To Apixaban
Bristol-Myers Squibb Co./Pfizer Inc. have evidence in hand that their investigational anticoagulant apixaban is useful in patients who can’t take warfarin. But any marketing gains for apixaban in this niche could be limited by physician skepticism about the patient population, assumptions that other similar drugs will be just as good in that population, and the recent FDA approval of the rival oral drug Pradaxa.
Doubts Linger Over Whether AVERROES Gives Any Advantage To Apixaban
Bristol-Myers Squibb Co./Pfizer Inc. have evidence in hand that their investigational anticoagulant apixaban is useful in patients who can’t take warfarin. But any marketing gains for apixaban in this niche could be limited by physician skepticism about the patient population, assumptions that other similar drugs will be just as good in that population, and the recent FDA approval of the rival oral drug Pradaxa.
Apixaban Impresses At ESC, Leading To Speculation About An Early Filing
Bristol and Pfizer put an early end to the Phase III study successfully comparing their anticoagulant to aspirin, and the preliminary data bode well for further results due out mid-2011, but will they wait?